BeyondSpring Q1 net loss from continuing ops $2.6M; Plinabulin data show promise in PD-1 resistant cancers

BeyondSpring Inc.

Net loss from continuing ops $2.6M, up 24% YoY; R&D expense $0.9M, G&A $1.7M.
Plinabulin combinations showed durable responses in metastatic NSCLC and Hodgkin lymphoma failing PD-1/L1 inhibitors.
SEED's RBM39 degrader achieved complete tumor regression in Ewing sarcoma models; IND filing on track for mid-2025.
SEED reported as discontinued ops after Jan 2025 sale of Series A-1 shares; BeyondSpring retains ~40% stake.
Phase 1 trial of Plinabulin + PD-1 inhibitor + radiation at MD Anderson showed >19-month duration in heavily pretreated Hodgkin lymphoma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.